Key insights
- A machine learning model identifies ANTX as a high-risk short candidate. The stock experienced a squeeze on no news, followed by management repricing options, suggesting potential selling pressure. A failed drug trial and the need for cash, coupled with an expiring shelf offering, further support the bearish outlook. This could negatively impact other speculative small-cap biotech stocks.
I developed a machine learning model that assigns a risk score to over 3,000 small-cap stocks to identify shorts. As of today, the #1 stock by risk score is ANTX. It recently ran from $1.06 to $6.91 on no news before fading to $3.77. During the run-up, management repriced their out-of-the money options to within the new price range, signaling intent to sell. The company has huge unused shelf capacity that is about to expire, and they need to raise cash because they have no revenues. Their top drug candidate just failed a clinical trial. If you want to know more, all of this is detailed in a research report that is available at Shortfinder (free registration required). I currently have no position in ANTX.